MDR、C-erbB-2和ER、PR在乳腺癌中的表达  

Expression of MDR、C-erbB-2、ER and PR protein in the breast cancer and clinical significance

作　　者：陶淑芳 马加东 曹金龙[2] 

机构地区：[1]上海市嘉定区安亭医院病理科,上海201805 [2]中国人民解放军第455医院病理科,上海200052

出　　处：《现代肿瘤医学》2004年第6期524-526,共3页Journal of Modern Oncology

摘　　要：目的　探讨乳腺癌中多药耐药基因产物P170糖蛋白、癌基因C -erbB - 2和雌激素受体 (ER)、孕激素受体 (PR)的表达情况及临床意义。方法　采用S -P免疫组化方法对 4 0例乳腺癌组织进行P170、C -erbB - 2和ER、PR表达的联合检测。结果　乳腺癌组织中P170、C -erbB - 2和ER、PR阳性表达率分别为32 5 %、35 %、6 2 5 %、30 %。P170的表达与术前化疗史及腋窝淋巴结转移呈正相关 ,与ER、PR的表达无显著相关性。C -erbB - 2表达与与腋窝淋巴结转移呈正相关 ,与ER、PR的表达呈负相关。ER的表达与组织学分级和腋窝淋巴结转移呈负相关 ,随着年龄增大表达率有升高趋势。结论　P170、C -erbB - 2和ER、PR与乳腺癌的发生发展有关。耐药基因P170的检测有利于指导乳腺癌的化疗和判断预后。C -erbB - 2可作为判断乳腺癌预后的重要指标。ER、PR测定可判断预后 ,有利于选择乳腺癌内分泌治疗。Objective To study the expression of P170、C-erbB-2、ER and PR in breast cancer and to evaluate their clinical significances.Methods Immunohistochemistry method was used to analyze the expression of P170、C-erbB-2、ER and PR in breast cancer.Results Positive expressions of P170、C-erbB-2、ER and PR in breast cancer were 32 5%、35%、62 5% and 30%respectively.P170 expression was positive relation to chemotherapy before surgery and lymph node metastasis,and it was not connection with the expression of ER and PR.Positive expression of C-erbB-2 was positive related to lymph node metastasis,and was negative related to ER and PR expression.The expression of ER and PR were negative connection with differentiation of breast cancer and lymph node metastasis.Conclusion Expression of P170、C-erbB-2、ER and PR are involved mainly in breast carcinogenesis and they are associated with prognosis of breast cancer.P170、ER and PR are in favor to direct therapy.

关 键 词：乳腺癌 耐药基因P170 癌基因C-ERBB-2 雌激素受体(ER) 孕激素受体(PR) 免疫组化 

分 类 号：R737.9[医药卫生—肿瘤]